 | | |
| Single-Dose Pharmacokinetics (PK), Safety and Tolerability of JNJ-64530440 (JNJ-0440), a Novel Hepatitis B Virus (HBV) Capsid Assembly Modulator (CAM), in Healthy Volunteers (HV)
|
|
| Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Dr. Thomas Kakuda1, Dr. Jeysen Yogaratnam1, Dr. Edward J. Gane2, Dr. Christian Schwabe2, Christopher Westland1, Jennifer Vuong1, Willem Talloen3, Oliver Lenz3, John Fry1, Ms. Sushmita Chanda1 and Dr. Pieter Van Remoortere4, (1)Alios Biopharma Inc., Part of the Janssen Pharmaceutical Companies, South San Francisco, CA, USA, (2)New Zealand Liver Transplant Unit, University of Auckland, Auckland, New Zealand, (3)Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium, (4)Janssen Research & Development, Janssen Pharmaceuticals, Titusville, New Jersey, USA 
|
|
| | |
|
|
